ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly revenue ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Operations (Postgres DB)
Latest, FY2025
65,179
Period ended Dec 31, 2025
Change on a year earlier
+44.7%
45,043 in FY2024
History
19 years
Since FY2007
Sources
13
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 65,179 | +44.7% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 45,043 | +32.0% | Form 10-K (filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 34,124 | +19.6% | Form 10-K (filed 2026-02-12) ↗ |
| FY2022 | Dec 31, 2022 | 28,541 | +0.8% | Form 10-K (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 28,318 | +15.4% | Form 10-K (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 24,540 | +9.9% | Form 10-K (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 22,320 | +3.8% | Form 10-K (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 21,493 | +7.6% | Form 10-K (filed 2020-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 19,974 | -5.9% | Form 10-K (filed 2020-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 21,222 | +6.3% | Form 10-K (filed 2017-02-21) ↗ |
| FY2015 | Dec 31, 2015 | 19,959 | +1.7% | Form 10-K (filed 2016-02-19) ↗ |
| FY2014 | Dec 31, 2014 | 19,616 | -15.1% | Form 10-K (filed 2015-02-19) ↗ |
| FY2013 | Dec 31, 2013 | 23,113 | +2.3% | Form 10-K (filed 2014-02-19) ↗ |
| FY2012 | Dec 31, 2012 | 22,603 | -6.9% | Form 10-K (filed 2013-02-21) ↗ |
| FY2011 | Dec 31, 2011 | 24,287 | +5.2% | Form 10-K (filed 2012-02-24) ↗ |
| FY2010 | Dec 31, 2010 | 23,076 | +5.7% | Form 10-K (filed 2011-02-22) ↗ |
| FY2009 | Dec 31, 2009 | 21,836 | +7.2% | Form 10-K (filed 2010-02-22) ↗ |
| FY2008 | Dec 31, 2008 | 20,372 | +9.3% | Form 10-K (filed 2010-02-22) ↗ |
| FY2007 | Dec 31, 2007 | 18,634 | – | Form 10-K (filed 2010-02-22) ↗ |
Breakdown
What makes up revenue ($m)
- Cost of sales ($M)11,052 · FY2025
- Research and development ($M)13,337 · FY2025
- Marketing, selling, and administrative ($M)11,094 · FY2025
- Asset impairment, restructuring, and other special charges ($M)484 · FY2025
- Interest expense ($M)895 · FY2025
- Interest income ($M) [reported separately through Q3 2025]175 · FY2024
- Other — net, (income) expense ($M)-571 · FY2025
- Income before income taxes ($M)25,731 · FY2025
- Income taxes ($M)5,091 · FY2025
- Net income ($M)20,640 · FY2025
- Earnings per share — Basic ($)23 · FY2025
- Earnings per share — Diluted ($)22.95 · FY2025
- Weighted-average shares outstanding — Basic (millions)897 · FY2025
- Weighted-average shares outstanding — Diluted (millions)899 · FY2025
Cite this data
StockData. (2026). Eli Lilly Revenue ($M) ($M), annual FY2007–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/fin_rev
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.